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ABSTRACT 
 
Rongqin Ren: The Essential Role of Bone Morphogenetic Protein (BMP)  
Signaling in Organogenesis 
(Under the direction of Cam Patterson) 
 
Signaling through the bone morphogenetic protein (BMP) pathway is essential to 
organ developments.  In this dissertation, two aspects of the BMP pathway were studied: 
downstream targets and extracellular regulators of BMP signaling.  To identify downstream 
BMP mediators in angiogenesis, we performed microarray analysis on endothelial cells 
(ECs) treated with BMP6 and identified cyclooxygenase 2 (Cox2) as a potential target of 
BMP6.  Upregulation of Cox2 as detected in the microarray was confirmed at the 
transcriptional level by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis 
and by reporter assays.  BMP6-induced endothelial cell proliferation, migration and tube 
formation activities were all blocked by selective pharmacologic inhibition of Cox2.  Both 
genetic deletion and pharmacologic inhibition of Cox2 markedly attenuated BMP6-
dependent angiogenesis in an aortic ring assay.  Targeted deletion of BMP-binding 
endothelial precursor-derived regulator (Bmper), encoding an extracellular regulator of 
BMP signaling, demonstrates its essential role as a BMP signal controller in early 
development.  Among other phenotypes, loss of Bmper activity caused abnormal branching 
 ii 
morphogenesis in the lung and induced hypertrophy in cardiomyocytes.   Transcriptional 
analysis using quatititive real-time PCR revealed the upregulation of hypertrophy markers 
and BMP signals in Bmper knockout cardiomyocytes and is consistent with a protective role 
for Bmper in cardiac hypertrophy via the downregulation of BMP pathway components.  In 
summary, this research implicates that both BMP downstream mediators and their 
extracellular regulators as potential therapeutic targets in physiopathological events 
associated with abnormal BMP activities. 
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CHAPTER I 
 
Introduction 
 
A. Organogenesis and Disease 
 During early development, organogenesis is an essential process describing the 
formation of the internal organs by the ectoderm, endoderm, and mesoderm.  Our research is 
focused on three aspects of development: vasculature development, lung morphogenesis, and 
heart formation. 
Vessel Development 
 Establishment of the vasculature during embryogenesis involves two distinctive 
processes: vasculogenesis and angiogenesis.  Vasculogenesis occurs when new blood vessels 
are generated de novo from blood islands in a highly regulated manner, while angiogenesis 
involves the formation of new blood vessels from preexisting vasculature 1.  The generation 
of the primary capillary plexus by vasculogenesis follows four important steps: 1) the 
generation of angioblasts; 2) angioblast aggregation and assembly into tube-like forms; 3) the 
construction of vessel lumens; and 4) the establishment of vascular networks 2,3.  The 
primary vasculature undergoes continuous remodeling into mature circulatory vessels by 
angiogenesis 4,5.  
 Angiogenesis is not only a required event during embryogenesis for the establishment 
of blood vessel networks and the circulatory system, but is also found in many pathological 
events in adults, such as rheumatoid arthritis, psoriasis, tumorigenesis, and diabetic 
retinopathy 6.  Angiogenesis can be roughly divided into two phases: the activation phase and 
 
 the maturation phase.  In the activation phase, endothelial cells (ECs) migrate into the 
extracellular space by penetrating the peri-vascular basement membrane.  They continue to 
proliferate and form capillary sprouts and tubular structures.  In the maturation phase, ECs 
stop migration and proliferation to reconstitute a basement membrane and vessel wall by the 
recruitment of smooth muscle cells.  During this highly regulated process, a balance between 
pro- and anti-angiogenic factors regulates the sequential steps of angiogenesis.  Several 
growth factors are considered to be pro-angiogenic in this process, including basic fibroblast 
growth factor (FGF), platelet-derived growth factor (PDGF), vascular endothelial growth 
factor (VEGF), and transforming growth factor beta 1 (TGF-β1).  Since ECs are essential 
components of angiogenesis, the abilities of these growth factors to stimulate angiogenesis 
are tightly associated with their effects on ECs.  For example, VEGF-C is able to promote the 
migration and proliferation of ECs in vitro and in vivo 7.  To illustrate the regulation of 
individual growth factor pathways and the cooperation among these angiogenic factors in 
angiogenesis is an area of study with much to be learned. 
Lung Morphogenesis 
 Normal embryonic development of lung is essential to initiate and maintain the 
oxygen exchange after birth.  In mouse, lung formation initiates at embryonic day 9.5 (E9.5) 
as a pair of primary buds that are formed with foregut originated endoderm evaginated from 
the laryngotracheal groove into the surrounding splanchnic mesenchyme8.  Early lung 
development can be divided into four stages.  First, the bronchial and respiratory bronchiole 
tree is formed during the pseudoglandular stage (E9.5- E16.6) 9.  Second, at the canalicular 
stage (E16.6- E17.4), the distal epithelium and mesenchyme undergo extensive branching 
into terminal sacs adjacent to the mesoderm-derived capillaries.  Third, terminal sacs and 
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 vasculature are further developed along with the maturation of alveolar epithelial type I and 
II cells during the terminal sac stage [E17.5 to postnatal day 5 (P5)].  Lastly, the alveolar 
stage (P5 to P30) is characterized by differentiation of the terminal respiratory sacs into 
alveolar ducts and sacs.   
The mature respiratory system is composed of different types of epithelial cells. The 
location along the proximal to distal airway determines the type of epithelial cells 9.  The 
larynx is lined with squamous epithelial cells.  The upper airways are characterized by a 
mixture of ciliated columnar and mucus-secreting goblet cells with clusters of pulmonary 
neuroendocrine cells (PNECs) 10.  The primary bronchioles contain clara cells, which are 
important for detoxifying harmful substances 11.  The terminal alveolar sacs are composed of 
two types of epithelial cells.  Type I epithelial cells enable gas exchange with the circulation 
by forming tight junctions with the pulmonary endothelial cells.  Type II epithelial cells 
secrete surfactant proteins, which are essential to reduce surface tension of alveoli and 
facilitate their expansion 12,13. 
Many growth factor pathways are involved in lung branching morphogenesis and 
epithelial cell differentiation.  For example, genetic deletion of fibroblast growth factor 10 
(Fgf10) in the lung mesenchyme or FGF10 receptor (Fgfr2IIIb) in the epithelium lead to 
severe pulmonary agenesis, which indicates the essential role of the FGF pathway in early 
lung morphogenesis 14,15.  Another important growth factor is sonic hedgehog (SHH).  
Several human congenital pulmonary defects have been related to abnormalities in the SHH 
signaling 16-19.  The Shh deficient lungs display a hypoplastic phenotype, missing distal lung 
tissues, and delaying type II epithelial cell differentiation 20-22. 
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 Cardiac Development 
Congenital heart diseases are among the most common human birth defects, and 
occur in approximately 1% of the newborn population 23.  Two major forms of these 
malformations are cardiac septation defects and valvular anomalies, which are related to 
problems in cardiac cushion formation and valve development.  At E8.0, the mouse heart has 
a tubular structure formed by a myocardial outer layer and an endocardial inner layer 24-26.  
The linear heart tube undergoes elongation and looping to generate these major components 
from anterior to posterior, including outflow tract (OFT), primitive ventricle, atrioventricular 
canal (AVC), atria and inflow tract 26,27.  Following the looping of heart, ECs in the AVC and 
OFT start an epithelial-to-mesenchymal transformation (EMT) to form the AVC cushions 
located between the future atria and ventricle around E9.5, and to contribute to the 
endocardial ridges at the OFT slightly later.  The OFT is closed to separate the aorta from the 
pulmonary trunk by the fusion of the endocardial ridges.  These cushion formations result in 
left to right separation of the heart 28.   
Another important event for heart formation is valvulogenesis.  Cardiac valves start to 
develop along with the endocardial cushion formation at the AVC and OFT region during the 
looping stage at E9.5 29.  Within the endocardial cushions undifferentiated heart valve 
progenitor cells first undergo proliferation followed by the remodeling stage, including 
decreased proliferation and production of extracellular matrix layers abundant in collagen, 
elastin and proteoglycan.  At the end, endocardial ridges contribute to the semilunar valves 
located in the aorta and pulmonary artery, while the leaflets of the mitral and tricuspid valves 
are derived from the AVC cushion and direct the blood flow from atria to ventricles 29-31. 
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 Multiple growth factor pathways are involved in normal heart formation. The lack of 
FGF10 causes defects in the positioning of heart in the thoracic cavity, while the loss of 
Fgfr2IIIb leads to malformations in the OFT septation and ventricular morphogenetic 
abnormalities 32.  The ablation of either one of two members of the FGF family, Fgf8 and 
Fgf15, results in abnormalities in OFT and the right ventricle during early heart development 
33,34.  Heparin-binding EGF-like growth factor (HB-EGF) is essential for cardiac valve 
formation and normal function 35.  The cardiac defects of Pdgfb null mice induce dilated 
ventricular chambers, reduced ventricular wall thickness, myocardial hypertrabeculation and 
septal malformations 36-39. 
B. TGF-β superfamily  
 
FIG. 1.1. TGF-β pathway components and its Smad-dependent and independent signaling. 
The bone morphogenetic protein (BMP) family belongs to the TGF-β superfamily, 
which is composed of three other major sub-families: the Mullerian inhibitory substance 
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 (MIS) family, the inhibin/activin family, and the TGF- β family 40,41.  An overall brief 
introduction of TGF-β signaling is described below as the BMP signal pathways share many 
similarities with the rest of the members.  
TGF-β ligands 
TGF-β superfamily ligands are synthesized as large precursor proteins which are 
proteolytically cleaved at the amino-terminal (N-terminal) and the mature carboxy-terminal 
(C-terminal) region are secreted into extracellular matrix 41-44.  The active C-terminal domain 
contains a “cysteine knot” folding motif formed by six intra-strand disulfide bonds 45-50.  
Except for growth and differentiation factor 3 (GDF3) and GDF9 51, TGF-β superfamily 
members possess the conserved seventh cysteine residue that can covalently bind to 
extracellular domains of their cell surface receptors 50,52,53.   
TGF-β receptors 
Receptors for TGF-β superfamily members are formed with an extracellular ligand-
binding domain, a single trans-membrane, and an intracellular serine-threonine kinase 
domain 54-57.  Receptors are divided into two groups, types I and II receptors.  Only type I 
receptors have a glycine-serine rich juxta-membrane domain (the GS box), which is essential 
for their activation 58.  Seven different type I receptors have been identified, including activin 
receptor-like kinase (Alk) 1 to 7 59,60.  Five total type II receptors contain TGF-β receptor II 
(TGF-βRII), BMPRII, Activin type II A receptor (ActRIIA), ActRIIB, and MISRII 55,57,61,62. 
BMP and activin membrane bound inhibitor (BAMBI) is a pseudoreceptor for the 
TGF-β pathway. 63  This protein has the extracellular ligand-binding and trans-membrane 
domains that resemble type I receptors, but it lacks the intercellular kinase activity.  Due to 
its special structure, BAMBI is able to compete with type I receptors for ligand interaction 
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 and block the downstream signaling of the TGF-β family 63,64.  BAMBI is coexpressed with 
BMP4 during development 63-65 and its expression is induced by TGF-β and BMP signaling, 
resulting in negative-feedback regulation 66,67. 
Structure and function of Smads 
Upon ligand binding, type I TGF-β receptors are trans-phosphorylated by the 
constitutively phosphorylated type II receptor 58.  The activated type I receptor 
phosphorylates receptor-regulated Smads (R-Smads), which in turn bind to the common 
partner Smad (Co-Smad) 68,69.  In vertebrates, Smad was named by combining Drosophila 
mother against decapentaplegic proteins (Mad) and the related C. elegans Sma 70.  These 
heteromeric complexes translocate to the nucleus and regulate the transcription of target 
genes by interacting with other transcription factors 68,71.  In mammalians, Smads can be 
divided into three functional groups: the R-Smads (Smad1, Smad2, Smad3, Smad5, and 
Smad8), Co-Smad (Smad 4), and Inhibitory Smads (I-Smads, Smad6 and Smad7) 72.   
 
Fig. 1.2. Difference in protein structures of R-Smads, Co-Smads, and I-Smads. MH1: Mad 
Homology 1; PY motif: PXXY site, which binds to Smurfs; SxS: phosphorylation site for type 
I receptors; NES: nucleus export signal. 
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 Smad proteins consist of two conserved globular domains: the N-terminal Mad 
Homology1 (MH1) domain and C-terminal MH2 domain, which are connected by a linker 
region 73,74.  The MH1 domain is only found in R-Smads and Smad4 but not I-Smads, and the 
MH2 domain is shared in all Smads 75.  The featured structures and functions of each domain 
are described as follows.  First, the MH1 domain contains a β-hairpin structure, which is 
important for its DNA-binding activity 76.  Second, in the linker region, R-Smads have 
multiple phosphorylation sites for Mitogen Activated Protein Kinases (MAPKs) 70,77, Ca++- 
and Calmodulin-dependent kinase II (Cam Kinase II) 78, Cyclin-dependent kinase (CDKs) 79, 
and G protein-coupled Receptor Kinase 2 (GRK-2) 80.  These phosphorylation events inhibit 
the functions of R-Smads in transducing TGF-β signaling 78,80-82.  Both R-Smads and I-
Smads have a PY motif (PPXY sequence) recognized by the E3 ubiquitin ligases, Smad 
ubiquitin regulatory factor 1 (Smurf1) and Smurf2, leading to the degradation of R-Smads 83-
85 or TGF-β receptors 86,87, respectively.  A functional leucine-rich nuclear export signal 
(NES) is only found in the linker region of Smad4 and is important for exporting Smad4 
from nucleus to cytoplasm under unstimulated conditions 88.  Finally, the conserved MH2 
domain mediates multiple protein-protein interactions, including the dimerization of R- and 
Co-Smads 89,90, the interaction between I-Smads and type I receptors 91,92, and the binding of 
R- and Co-Smads with transcriptional coactivators such as p300 and the cAMP-response 
element-binding protein (CREB) binding protein (CBP) 93-96.  R-Smads have an additional 
Ser-X-Ser motif at the C-terminal that is phosphorylated by activated type I receptors and 
this modification is required for downstream signaling 69,97-99.   
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 Transcriptional activity of Smads 
 R-Smads and Co-Smads complexes bind to the Smad-binding element (SBE) on the 
promoter region which transcriptionally regulates the expression level of the TGF-β 
downstream targets.  Currently, the known SBEs include: 1) CAGA motif (CAGACA), 
which is found in the promoters of many TGF-β and BMP target genes 75,100-104; 2) GTCT 
motif (GTCTAGAC) 104; and 3) GCCG motif (GCCGnCGC) 66,105,106.  The low affinity of 
Smad proteins for the SBE motifs does not secure the interaction of a Smad complex to one 
SBE site in vivo 103.  In in vitro assays, this problem can be overcomed by using concatemers 
with multiple SBEs to increase the binding affinity for transcriptional activation 104.  Since 
the promoters of Smad targets contain fewer repeats of SBEs in vivo, the high affinity of the 
Smad complex to DNA is achieved by cooperating with DNA-binding cofactors 107.  The 
different combination of Smad partners in various tissues and cell types can also help to 
determine the activation or repression of the transcription of specific genes.  One example of 
Smad-binding co-transcription factors is the forkhead family protein, FoxH1.  The interaction 
between FoxH1 with Smad2/Smad4 complex is essential for the binding of the complex to 
the Mix2 promoter region, which leads to transcriptional activation of this promoter 108,109 
Smad-independent signaling 
 In addition to the Smad-dependent signaling pathway, the TGF-β-activated kinase 1 
(TAK1) pathway is one of the Smad-independent signal pathways that transduce TGF-β 
downstream effects 110.  Upon the binding of TGF-β ligands to their receptors, TAK1 activity 
is stimulated through TAK1-binding protein (TAB1) and X-chromosome-linked inhibitor of 
apoptosis (XIAP), an E3 ubiquitin ligase 111.  TAK1 is reported to activate the p38 MAPK 
and c-Jun N-terminal kinase (JNK), which mediates the apoptotic effect induced by TGF-β 
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 signaling 112-115.  TGF-β pathway can also interact with Ras , Erk and the 
phosphatidylinositol 3-kinase (PI3K) signaling and this crosstalk is important for TGF-β 
induced apoptosis, proliferation, and differentiation 116,117. 
Different functions of TGF-β sub-families 
Each subfamily of the TGF-β superfamily has its distinctive function in development. 
MIS functions as an important inducer for regression of the embryonic Mullerian duct in 
males 118.  The inhibins and activins are well known by their ability to regulate biosynthesis 
and secretion of follicle-stimulating hormone, a key hormone in the regulation of follicle 
release from the ovaries 119-121.  The TGF-β sub-family consists of 3 isoforms: TGF-β1, TGF-
β2, and TGF-β3 41, which regulate multiple events during embryonic development, including 
yolk sac vasculogenesis, haematopoiesis, cardiac development, and lung morphogenesis 122-
124. BMPs were originally found to induce ectopic bone formation when implanted into 
muscle 125.  Later studies connected BMPs to other processes in development, such as 
anterior-posterior axis formation, neurogenesis, and gonadogenesis 126-128.  The contribution 
of BMPs to vessel, lung, and heart developments is described below. 
C. The BMP signal pathway 
Similar to the rest of TGF-β members, BMPs are synthesized as large precursor 
proteins, which are proteolytically cleaved at an Arg-X-X-Arg site located at the N-terminus, 
and then the mature C-terminal region is secreted into the extracellular matrix 44.  Over thirty 
members of the BMP family have been identified from different species 126,129.  In mammals, 
the BMP family is composed of the BMP group (BMP2 to BMP17) and the GDF group 
(GDF1, 3, 5, 8, 9, 10) 130.  For BMP signaling, there are currently four major BMP type I 
receptors: Alk1, Alk2, Alk3 (BMP type IA receptor, BMPR-IA), and Alk6 (BMPR-IB); and 
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 three type II receptors: BMP RII, Activin type II A receptor (ActR-IIA) and ActR-IIB 
60,131,132 133.  The R-Smads for BMP downstream signaling are Smad1, Smad5, and Smad8 
134.  A list of BMP direct target genes, which mediate BMP-dependent functions in different 
cells and tissues have previously been identified, including Xvent2, Xvent2B, msx1, msx2, 
Id1, Id2, Id3, GATA2, Dlx5, Tob, and FGFR2 106,135-142. 
The BMP pathway can also activate both Smad-dependent and independent signals.  
There are two forms of type I and type II receptor complexs on the cell surface:  One is the 
preformed receptor complex (PFC) and the other is BMP-induced signaling complex (BISC).  
The stimulation of PFC by BMP ligands initiates the activation of the Smad signaling, 
whereas ligand-induced complex, BISC, directs signals through the Smad-independent, p38 
MAPK-dependent pathway, which results in the induction of alkaline phosphatase 143. 
BMP pathway in angiogeneisis 
BMPs have important but incompletely understood effects on angiogenesis by 
affecting EC differentiation, migration and proliferation. BMP4 induces EC differentiation of 
mouse embryonic stem cells, and this induction is blocked by the expression of a dominant 
negative BMP receptor 144,145.  In developing Xenopus embryos, progenitor cells in dorsal 
and ventral marginal zones fail to differentiate into ECs in the ventral blood island region 
when BMP signaling is blocked by injection of RNA coding for a dominant negative, 
truncated form of the BMP type I receptor 146 . Both BMP2 and BMP4 stimulate EC 
migration and tube formation activity, which contribute to their ability to promote 
neovascularization in tumors147,148.  BMP6 is a potent agonist for EC migration and tube 
formation in vitro 149.  On the other hand, the transcorneal injection of BMP4 in rats 
promotes apoptosis of capillary ECs 150, suggesting that BMP4 contributes to EC apoptosis 
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 during rat papillary membrane regression. Taken together, these studies demonstrate an 
important yet complex role for BMPs in angiogenesis. 
BMP pathway in lung morphogenesis   
Several BMPs and their receptors have been found to be expressed during lung 
development.  During the pseudoglandular and canalicular stages, Bmp4 is expressed in both 
the distal tips of the epithelium and in the mesenchyme adjacent to the more proximal 
developing airways.  Bmp4 expression is downregulated in the epithelium of the terminal 
sacs but remains in the capillary endothelium prior to birth 151.  On the other hand, Bmp5 and 
Bmp7 expression predominantly exist in the mesenchyme and endoderm, respectively152,153.  
Three type I receptors mediating BMP signaling are also expressed in the embryonic lung.  
Alk2 is found in mesenchyme specifically, while Alk3 and Alk6 are localized in both the 
epithelial and mesenchymal populations154,155. 
The functional importance of BMPs in lung morphogenesis has been supported by 
transgenic and knock-out studies of BMP ligands and their receptors.  Most lines of evidence 
suggest that BMP signaling positively regulates the proliferation of the distal epithelium.  
BMP4 promotes branching morphogenesis of the whole embryonic lung culture 156, while 
inhibition of BMP signaling by overexpression of BMP4 antagonist Noggin or Gremlin 
results in reduction in lung size and an expansion of proximal bronchial epithelium to the 
periphery157,158.  Conditional deletion of Alk3 in lung epithelium leads to a decline in 
proliferation, an increase in apoptosis, and defects in morphogenesis159.  However, BMP4 
transgenic lungs are smaller in size, have fewer and cystic epithelial terminal sacs, and have 
decreased cell proliferation153.  This finding indicates that BMP4 activity at very high levels 
may activate different pathways, which elicit negative responses to proliferation.  Taken 
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 together, BMP signals play an essential role in lung branching morphogenesis and 
homeogenesis. 
BMP signals in heart development 
BMP signals are involved at different stages of cardiac development, including the 
initial stage of cardiac myogenesis and the later stage of endocardial cushion development 
and cardiac valve maturation160-163.  BMP ligands are present in heart during early embryonic 
development.  During E9.5 and E10.5, Bmp2 is expressed in the AVC region, while Bmp4 
expression is located at the OFT area and endocardial cushion164.  The dynamic Bmp6 
expression starts in the endocardium at E9.5, then in the AVC cushions and in the myocardial 
layer of the left part of the OFT at E10.5, and is localized to the mesenchyme of the OFT at 
E12.5163,165.  The distribution of Bmp7 transcripts is ubiquitous throughout the myocardium 
from E8.5 to E15.5166,167.   Receptors transducing BMP signals, including Alk2, Alk3 and 
BMPRII are also ubiquitously expressed in the developing heart 154,155,168,169.  Some of the 
BMP antagonists are also present at the heart forming region.  Noggin mRNA is detected in 
the heart forming area as early as E7.5170 and its expression remains in the ventricles and  the 
myocardium of the AVC and OFT between E11.5 to E12.5171.  
Conditional knock-down of Bmp2 in the heart leads to reduced mesenchymal 
components inside the AV cushions172,173, while BMP4 deficiency results in malformations 
in proximal OFT septation and decreased proliferation of OFT mesenchyme174.  Individual 
disruption of Bmp5, Bmp6, and Bmp7 expression does not show obvious cardiac 
abnormalities due to functional redundancy 175-177.  The Bmp5 and Bmp7 double knockout 
mouse has severe defects in cushion formation 167, while Bmp6 and Bmp7 double deletion 
also results in malformation in cardiac cushion163.  Cardiac deletion of Alk3 results in a 
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 hypoplastic AV cushion due to impaired epithelium-mesenchymal-transformation (EMT) 
178,179.  Homozygous BmprII∆E2/∆E2 mice, which express a mutant BMPRII lacking the ligand-
binding domain, show malformed septation of the conotruncus and absence of the semilunar 
valves 162.  Conditional Noggin-/- mice display thicken ventricular walls and enlarged AVC 
and OFT regions a result of elevated cell proliferation and EMT activity 171.  Based on these 
studies, the BMP pathway is essential to the formation of cardiac cushions and valves during 
heart development. 
D. Modulation of BMP signaling 
The modulation of BMP signals takes place in three locations: the intracellular area, 
the plasma membrane, and the extracellular matrix.  Our research has been focused on 
studying extracellular antagonists, which bind to BMPs and interfere with their interaction 
with cell-surface receptors.  At least seven antagonists have been found in vertebrates, 
including Noggin, Chordin, Chordin like, Follistatin, FSRP, the DAN/Cerberus protein 
family, and sclerostin127.  These antagonists help to maintain proper levels of BMP signaling 
and play essential roles in organogenesis.  For example, Noggin and Chordin are important in 
developmental events, including neurogenesis and pharyngeal development 180-182.  
Bmper protein structure and expression  
 Previous studies in our lab found that Bmper mRNA is enriched in the fetal liver 
kinase (Flk1)-positive population in differentiated mouse ES cells144.  Bmper has a 39-
amino-acid signal peptide at the amino terminus, five cysteine-rich (CR) von Willebrand C- 
like domains, one von Willebrand D domain, and a carboxy-terminal Trypsin Inhibitor-like 
cysteine rich domain (Figure 1.3) 144.  Bmper protein shares 30% overall identity (44% 
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 similarity) with its Drosophila homolog, crossveinless2 (cv2)183.  The presence of CR 
domains indicates Bmper as a BMP binding protein like chordin.  The expression profile of  
 Bmper in both adult and embryonic mice was examined.  Bmper mRNA expression was 
highest in heart, lung and skin in adults144,183.  The expression pattern of BMPER in 
developing embryos is highly dynamic.  Bmper is first expressed in the proximal part of the 
embryonic region during mid-gastrulation 183.  At E10.5, in situ hybridization reveals Bmper 
expression in two important early angiogenesis regions, yolk sac where BMP2, BMP4 and 
BMP6 activity has been found184, and the aorto-gonadal-mesonephric (AGM) region, which 
contains EC cell precursors and where a high level of BMP4 is found185.  At E14.5, Bmper 
transcripts are found in lung mesenchymal tissues and cartilage of the developing skeleton 
183. Based on its structure and expression pattern, Bmper may play an important role in 
organogenesis where BMP signals are involved.   
Bmper 685 
751 
948 
CV2 
Chordin 
FIG. 1.3. Structures of CV2, and Chordin in comparison to that of Bmper. Total amino acid 
number of each protein is indicated at C-terminal end. CR: cysteine-rich; VWD: von Willebrand 
D domain; TI: Trypsin Inhibitor-like. 
Anti- and pro-BMP activity of Bmper 
The effect of Bmper on the BMP pathway is closely related to its ability to bind to 
BMP2, BMP4, and BMP6 144.  Studies show evidence supporting both anti- and pro-BMP 
activity for Bmper.  For example, ectopic expression of Bmper dorsalizes Xenopus 
embryos144,186.  Bmper inhibits BMP-induced osteoblast and chondrocyte differentiation in 
vitro 187.  Bmper inhibits BMP4-stimulated luciferase activity in the Smad-dependent reporter 
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 assay and blocks BMP4-induced EC differentiation from ES cells 144.  On the contrary, other 
studies indicate that Bmper has pro-BMP effects.  Bmper activity is important for the 
formation of cross-veins in fly wing 188,189,190,191. Bmper enhances phosphorylation of Smad1 
stimulated by BMP4 in COS7 cells 192.  Injection of both Bmper and BMP4 RNA in animal 
caps synergistically induces the expression of the mesoderm marker, Xbra 186.  A hypothesis 
proposed by Hammerschmidt’s group suggests that Bmper activity on BMP signaling is 
dependent on its proteolytic processing; uncleaved Bmper is an anti-BMP regulator, whereas 
cleaved Bmper plays a pro-BMP role because only uncleaved Bmper can bind to the 
extracellular matrix through heparin 193.  
 
FIG. 1.4. The interaction of twisted gastrulation, chordin and BMP. Tsg stabilizes the chordin 
and BMP complex to inhibit BMP signals.  In the presence of Tolloid, Tsg facilitates the cleavage 
of chordin and blocks the binding of cleaved fragments to BMP.  This leads to an activated BMP 
pathway. 
This proteolysis-dependent pro-BMP activity is also observed on two BMP 
antagonists, Chordin and Twisted gastrulation (Tsg) (Figure 1.4).  First, full length chordin 
directly binds to BMP through its four CR domains 194.  This binding is stabilized by Tsg and 
a trimolecular BMP–Tsg–Chordin complex is formed 195,196.  This complex sequesters BMP 
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 from its cell surface receptors, which results in inhibition of BMP signaling196-200.  
Tolloid/Xolloid proteases cleave chordin and release BMP, which in turn activates 
downstream signaling201-204.  This proteolytic cleavage of Chordin by Tolloid/Xolloid is 
facilitated by Tsg 198,199,204.  Cleaved Chordin fragments containing CR domains are still able 
to bind and inhibit BMP and this remaining inhibitory activity is also blocked by Tsg 
194,195,199,205.  Thus, the presence of Tolloid/Xolloid can determine the anti- or pro-BMP 
activity of Chordin and Tsg.  Based on this model, the different action of Bmper on BMP 
signaling may also be affected by the expression of an unidentified protease, which cleaves 
Bmper proteins. 
  Despite structural similarity of Bmper and Chordin, there are two important 
differences between these two BMP extracellular regulators.  First, Bmper is expressed in 
areas where high BMP activity has been found and its expression is BMP signaling 
dependent 184,193.  On the other hand, Chordin transcripts, are found in regions with low BMP 
activity and its expression is negatively regulated by BMP signaling 181,206.  Second, the 
binding of Bmper to BMPs does not block their interaction to cell surface receptors 193, while 
the Chordin and BMPs complex cannot bind to the receptors 194.  This suggests that Bmper 
may have its own regulatory mechanism different from the previously described mode for 
Chordin and Tsg. 
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 Abstract 
 
The bone morphogenetic protein (BMP) family of proteins participates in regulation 
of angiogenesis in physiological and pathological conditions. To investigate the molecular 
mechanisms that contribute to BMP-dependent angiogenic signaling, we performed gene 
expression profiling of BMP6-treated mouse endothelial cells. We detected 77 mRNAs that 
were differentially regulated after BMP6 stimulation. Of these, cyclooxygenase 2 (Cox2) was 
among the most highly upregulated by BMP stimulation, suggesting a role for Cox2 as a 
downstream regulator of BMP-induced angiogenesis. Upregulation of Cox2 by BMP6 was 
detected at both mRNA and protein levels in endothelial cells, and BMP6 increased 
production of prostaglandins in a Cox2-dependent fashion. BMP6 upregulated Cox2 at the 
transcriptional level through upstream SMAD-binding sites in the Cox2 promoter. 
Pharmacologic inhibition of Cox2, but not Cox1, blocked BMP6-induced endothelial cell 
proliferation, migration and network assembly. BMP6-dependent microvessel outgrowth was 
markedly attenuated in aortic rings from Cox2–/– mice or after pharmacologic inhibition of 
Cox2 in aortas from wild-type mice. These results support a necessary role for Cox2 in 
mediating proangiogenic activities of BMP6. These data indicate that Cox2 may serve as a 
unifying component downstream of disparate pathways to modulate angiogenic responses in 
diseases in which neovascularization plays an underlying pathophysiologic role. 
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 Introduction 
During the tightly regulated process of angiogenesis, a balance between pro- and anti-
angiogenic factors results in the sequential steps required for new blood vessel formation. 
Several mitogens are considered pro-angiogenic, including members of the basic fibroblast 
growth factor, platelet derived growth factor, vascular endothelial growth factor, and 
transforming growth factor beta families. Since endothelial cells (ECs) are essential 
components of angiogenesis, the abilities of these growth factors to stimulate angiogenesis 
are tightly associated with their effects on ECs. 
BMPs belong to the TGF-β superfamily, and over thirty members of the BMP family 
have been identified from different species 126,129. BMPs are synthesized as precursor 
proteins, then are proteolytically cleaved at the N-terminus and secreted into the extracellular 
matrix. BMPs dimerize through disulfide bonds and initiate signaling by binding 
cooperatively to both type I and type II membrane-bound serine/threonine kinase 
receptors207,208. The constitutively active type II receptors trans-phosphorylate type I 
receptors, which then activate intracellular substrates by phosphorylation, and thus determine 
the specificity of intracellular signals. In vertebrates, small mothers against decapentaplegic 
proteins (Smads) are downstream signaling molecules for the receptors. Receptor-regulated 
Smads (R-Smads) bind to the common partner Smad (Smad4), and these heteromeric 
complexes translocate to the nucleus and regulate the transcription of target genes by 
interacting with other transcription factors at cis-acting elements defined by the sequence 
CAGAC[A] 209,210. 
BMPs have important but incompletely understood effects on angiogenesis by 
affecting EC differentiation, migration and proliferation. BMP6 is a potent agonist for EC 
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 migration and tube formation in vitro 149. BMP2 enhances neovascularization in tumors and 
this activity may involve the stimulation of EC proliferation, migration, and tube formation 
by BMP2 147. BMP4 induces EC differentiation of mouse embryonic stem cells, and this 
induction is blocked by the expression of a dominant negative BMP receptor 144,145. On the 
other hand, the transcorneal injection of BMP4 in rats promotes apoptosis of capillary ECs 
150, suggesting that BMP4 contributes to EC apoptosis during rat papillary membrane 
regression. In developing Xenopus embryos, progenitor cells in dorsal and ventral marginal 
zones fail to differentiate into ECs in the ventral blood island region when BMP signaling is 
blocked by injection of RNA coding for a dominant negative, truncated form of the BMP 
type I receptor 146 . Taken together, these studies demonstrate an important yet complex role 
for BMPs in angiogenesis. 
Though many lines of evidence indicate that BMPs are important in angiogenesis, 
there are still unresolved issues, in particular the delineation of downstream effectors that 
respond to BMP signaling during angiogenesis. This study has taken advantage of microarray 
technology to analyze the BMP6-mediated signaling network in ECs. Among the list of 
differentially expressed genes, we have selected Cox2 for further analysis based on the 
sustained change in transcription levels. Cox2, which catalyses the conversion of arachidonic 
acid to prostaglandins (PGs), is linked to several physiological and pathogenetic pathways 
that participate in angiogenesis, inflammation and invasiveness 211. The increased risk of 
heart attack and stroke among patients taking Cox2 inhibitors 212-216 indicates a complicated 
role for Cox2 activity in maintaining vascular homeostasis. Our expression and EC 
functional studies indicate that Cox2 is an essential downstream component mediating 
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 BMP6-dependent EC activation, which could be one of the mechanisms underlying its 
cardioprotective effects. 
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 Materials and methods 
Plasmids and reagents 
Recombinant human BMP6 protein was obtained from R&D systems. A selective 
Cox2 inhibitor, NS398, the Cox1 inhibitor, SC560, and immunoassay kits for PGE2 and 6-
keto-PGF1α were obtained from Cayman (Ann Arbor, MI). Cox2 promoter regions from –
8653 to +53 bp and –7444 to +53 bp were inserted into pGL3-Basic vector (Promega, 
Madison, WI). Two similar Cox2 reporter constructs (–1500 to +1 bp and –371 to +70 bp) 
were kindly provided by Dr. Curtis C. Harris from National Institutes of Health 217 and Dr. 
Carol C. Pilbeam from University of Connecticut 218. 
Microarray analysis 
Mouse intraembryonic endothelial cells (MECs) were cultured as previously 
described 9. Total RNA was extracted from MECs treated with BMP6 for 4, 12, or 24h, or 
from mock-treated controls. Universal mouse reference RNA was used as a reference 219, and 
was labeled with Cy3 florescence dye using the Fluorescent Linear Amplification Kit 
(Agilent Technologies, CA). Samples of MEC RNA were labeled with Cy5, and equimolar 
mixtures of the two florescence dye-labeled probes were hybridized to Agilent 22k Mouse 
Development Oligo Microarrays (G4120A, Agilent Technologies). Microarrays were 
scanned with a GenePix 4000B scanner and images were quantified with GenePix Pro 5.0 
Software (Molecular Devices, Sunnyvale, CA). Each experimental group included 
independent triplicate biological replications. Raw expression data were normalized via a 
modified quantiles local algorithm (X. He and C. Patterson, manuscript in preparation). 
Differentially expressed genes were identified with a two-tailed type 2 Student t-test. Cluster 
analysis and visualization using Java-TreeView were accomplished as previously described 
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 220.   Selected genes were validated by RT-PCR. The complete, MIAME-compliant dataset is 
available at the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/projects/geo/, 
reference # GSE4909). 
Reporter gene analysis and gel mobility shift assays 
Luciferase reporter assays were performed as previously described 144. 
Electrophoretic gel mobility assays (EMSA) were performed essentially as described 134 with 
3 μg of nuclear extract. DNA and protein complexes were resolved on a non-denaturing 4% 
polyacrylamide gel and visualized by autoradiography. The probes used were –8147—AGG 
CAG ACA GAC AGA CAA CCA GAT AGA TA— –8119 (sense) and –8119— TCC GTC 
TGT CTG TCT GTT GGT CTA TCT AT— –8147 (antisense). 
Cell proliferation, migration and tube formation assays 
Cell proliferation assays were performed as described previously 221. The migration 
assays were prepared using a 48-well chamber apparatus (NeuroProbe, Cabin John, MD). 
The lower chambers of the apparatus were filled with DMEM with or without BMP6 and 
then covered with the gelatin-coated filter and the upper chambers. Cell suspensions in 
DMEM with or without Cox inhibitors were then added to the upper chambers. After 
incubating for 6 h at 37°C, cells present on the lower surface were identified with the 10 X 
objective on a Nikon Eclipse TS100 inverted microscope. EC tube formation was analyzed 
with the Matrigel-based tube formation assay 149. Chilled 24-well plates were coated with 
Matrigel (Becton Dickinson) that was polymerized at 37°C for 30 minutes. MECs were 
serum-starved overnight, trypsinized, and plated at equal numbers into each Matrigel-coated 
well. After 16 h of incubation in the absence or presence of BMP6 and/or Cox inhibitors, the 
formation of tubes was photographed. Images were processed with Adobe Photoshop® CS. 
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 Mouse aortic ring angiogenesis assays 
Mouse aortic ring assays were performed with modifications from a previously 
reported method 222. Thoracic aortas were removed from 2 month old mice, aortic rings were 
sectioned and then embedded in rat tail collagen gel (1.5 mg/ml) prepared by mixing 7.5 
volumes of 2 mg/ml collagen, 1 volume of 10X MEM, 1.5 volume of NaHCO3 (15.6mg/ml) 
and 0.1 volume of 1M NaOH. Each well containing the aortic rings was incubated in 250 μl 
of MCDB131 supplemented with 25 mM NaHCO3 and 1% mouse serum.  Images of aortic 
rings were taken with an Olympus microscope at Day 6. 
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 Results 
Characterization of the BMP-responsive transcriptome in ECs 
We utilized MECs to characterize BMP6-responsive transcriptional events in ECs for 
two reasons. First, MECs express all the components of the BMP signaling pathway from 
cell surface receptors to Smads (data not shown). Second, Id1, a well-characterized target of 
BMP6 signaling in ECs 149, is faithfully upregulated in MECs (Figure 2.1). To characterize 
the BMP6-dependent transcriptome in ECs, RNA samples extracted from MECs with or 
without BMP6 treatment for 4, 12, or 24 h were analyzed with microarrays. Differentially 
expressed genes were identified by Student’s ttest (p< 0.05) and then filtered for fold change. 
As expected, Id1 was upregulated at each time point in this analysis, confirming the validity 
of our dataset and the sensitivity of this approach for identifying BMP-responsive genes 
(Table 2.2). 
Out of 20,000 genes surveyed, a total of 37 genes were upregulated and 40 genes 
were downregulated by treatment with BMP-6 at any time point using relatively stringent 
criteria to reduce false-positive results (representative genes shown in Tables 2.1 and 2.2). 
Two groups of differentially expressed genes were identified by hierarchical clustering 
analysis (Figure 2.2). The first group comprised genes downregulated by BMP6, including 
two members of the metalloproteinase family (Adamts1 and Adamts5) that are known 
inhibitors of neovascularization 223. The second group contains genes upregulated by BMP6. 
Wnt2, Cox2, Id1, two other members of the Id family (Id2 and 3), CD44, Tnfrsf12a (tumor 
necrosis factor receptor superfamily), Snail1 (a Wnt-regulated transcriptional factor) and 
Timp1 (an inhibitor of metalloproteinases) are present in this cluster. To establish the validity 
of the microarray dataset, we performed RT-PCR analysis for several selected genes, 
 26 
 confirming that Cox2, Wnt2, Timp1 and Adamts1 were indeed differentially regulated by 
BMP6 at the mRNA level (Figure 2.3A). In addition, the upregulation of Cox2 after BMP6 
treatment was also demonstrated at the protein level by Western blotting (Figure 2.3B). 
Enhanced production of prostanoids through the upregulation of Cox2 by BMP6 
Because cyclooxygenases catalyze the formation of prostaglandins from arachidonic 
acid, we next investigated whether stimulation of ECs by BMP6 also leads to increased PG 
production by MECs. These experiments were performed in the presence of arachidonic acid 
concentrations that favored prostaglandin generation by Cox2 over Cox1 and measured the 
two functional important PGs in ECs, PGE2 and the dominant form PGI2 224. BMP6 potently 
increased generation of PGE2 and 6-keto-PGF1α (a stable metabolism of PGI2) in MEC, as 
determined by accumulation of these prostanoids in the culture media after BMP stimulation 
(Figure 2.4A and B).  Generation of PGE2 and 6-keto-PGF1α was abolished by pretreatment 
with the Cox2 inhibitor NS398 but not the Cox1 inhibitor SC560, indicating their derivation 
via a Cox2-dependent mechanism. 
Transcriptional activation of the Cox2 promoter by BMP6 
Because Cox2 is primarily regulated at the transcriptional level by factors such as 
interleukin-1β 224,225 and tumor necrosis factor-α 226, we reasoned that the rapid upregulation 
of Cox2 mRNA by BMP6 might also occur at the transcriptional level. To investigate the 
mechanism of transactivation of the Cox2 promoter by BMP6, we tested four Cox2 
promoter-luciferase reporter constructs containing various lengths of Cox2 promoter regions 
upstream of its transcription start site (Figure 2.5A). These constructs were transiently 
transfected into MECs, which were then treated with or without BMP6. Only the –8653 to 
+53 bp promoter construct, but not those containing smaller fragments of the Cox2 promoter, 
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 could be stimulated by BMP6 (Figure 2.5B). In addition, we observed a 5 fold activation of 
this 8.7 kb reporter when Smad1 was co-transfected into MECs, which is consistent with 
previous observations that overexpressed Smad proteins can transactivate BMP target genes 
in a ligand-independent manner 227,228. These data indicate that necessary BMP-responsive 
elements in the Cox2 promoter are located between base pairs –8653 and –7444. 
Interestingly, this interval in the Cox2 promoter contains a tight cluster of putative 
Smad-binding elements (identified using the Vector NTI algorithm) between base pairs –
8147 and –8119 (Figure 2.5A). To further characterize the BMP6-responsive element in the 
Cox2 promoter, we used this 29-bp sequence as a probe in gel shift assays after performing 
pilot experiments to exclude the possibility that other potential Smad-binding sites within the 
promoter had nuclear protein-binding activity. Using this 29-bp fragment as a probe, we 
found that extracts from MECs contained a DNA binding activity that migrates with slower 
mobility than the probe alone (Figure 2.5C). This binding was competed away by addition of 
unlabeled specific probe at 50-fold excess but not by 100-fold excess of unlabeled 
nonspecific competitor, indicating its specificity.  To analyze whether this binding is related 
to Smad-binding activity, we tested a consensus Smad-binding element sequence in 
competition assays 229. This sequence efficiently inhibited binding of the labeled probe to 
nuclear proteins, which strongly suggested that Smads are required nuclear proteins in the 
extract for binding to the 29-bp Cox2 element. Stimulation of MECs with BMP6 for 4 h 
retarded the mobility and enhanced the intensity of the DNA-protein interaction (Figure 
2.5D), suggested that BMP6 remodels or post-translationally modifies the protein complex 
that binds to this element. In addition, the coexpression of Flag-tagged Smad1 and Smad4 
caused an additional DNA-protein complex of slightly slower mobility. Known difficulties in 
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 supershifting Smad proteins preclude definitive testing that the endogenous complexes 
contains proteins within this family, but our data are most consistent with a necessary role for 
Smad binding within the Cox2 promoter in mediating BMP6-dependent trans-activation. 
Inhibition of Cox2 blocks BMP6-induced EC proliferation, migration and tube formation 
To determine whether the upregulation of Cox2 plays a necessary intermediary role in 
BMP6-dependent endothelial functions, we examined whether changes in BMP6-mediated 
MEC proliferation and migration occur after inhibition of Cox2. At the concentrations used 
here, NS398 exerted specific inhibition of Cox2 over Cox1, as determined by measurement 
of PGE2 production (data not shown). In cell counting assays as an index of proliferation, 
BMP6 stimulated cell growth at both 48 and 72 h after treatment (Figure 2.6A). Inhibition of 
Cox2 blocked BMP6-dependent MEC proliferation almost totally, whereas a specific Cox1 
inhibitor, SC560, had no effect. We next measured cell migration activity using two assays: 
wound healing and Boyden chambers. BMP6 potently enhanced migration through wells, as 
has been previously described 149, and the addition of NS398 prevented BMP6-stimulated 
migration whereas SC560 had no effect (Figure 2.6B). Similar results were observed in 
wound healing assays (data not shown). We also tested the role of BMP6-dependent Cox2 
activation on EC tube formation using Matrigel tube formation assays. The addition of BMP6 
alone increased the number of enclosing tubes by over 2-fold, and this increase could only be 
blocked by cotreatment with NS398, but not SC560 (Figures 2.6C and D). The results from 
these functional assays strongly support a model in which Cox2 is a necessary mediator of 
the effects of BMP6 on EC function. 
Requirement of Cox2 activity in BMP6-induced microvessel outgrowth 
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 To better understand the effect of Cox2 activity in BMP6-induced angiogenesis, 
mouse aortic ring assays were selected to mimic an in vivo environment 222. Mouse thoracic 
aortas were sectioned, embedded in collagen gel, and incubated with or without BMP6 
and/or Cox inhibitors. To minimize the background of microvessel outgrowth under control 
conditions, only 1% mouse serum was added to media. After a 6-day incubation, BMP6 
treatment increased the total number of outgrowing microvessels from aortic rings (Figures 
2.7A and B). Cotreatment with NS398 reduced BMP6-activated neovascular outgrowth to 
control levels, whereas SC560 had no effect. We also used genetic deletion of Cox2 to 
provide more definitive evidence of a role for endogenous Cox2 in mediating BMP6-
dependent responses. Aortas from Cox2 –/– mice and Cox2 +/+ littermates were used in 
these experiments. The activation of microvessel outgrowth by BMP6 was abolished in 
aortas from Cox2 –/– mice (Figures 2.7C and D). Although Cox2 activity may not be 
necessary for all VEGF-mediated events 230, VEGF induces Cox2 expression in ECs 231 and 
this induction is required for VEGF-mediated angiogenesis 232. Therefore we also tested the 
effects of Cox2 deletion on VEGF-induced neovascularization. The addition of recombinant 
VEGF (25 ng/ml) significantly increased microvessel outgrowth in WT aortas, but not in 
Cox2 –/– aortas (Figures 2.7C and D). These data indicate that BMP6 and VEGF signal 
pathways unexpectedly share common requisite downstream mediators in the regulation of 
angiogenesis. 
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 Discussion 
The BMP signaling pathway has an important but incompletely characterized role in 
mediating vascular development and angiogenesis. Mechanistically, little is known about 
downstream transcriptional targets of BMPs other than Id1 in EC 149. In the present study, we 
have been able to generate a comprehensive list of BMP6 target genes in ECs using 
microarray technology. The accuracy of our dataset has been confirmed by both RT-PCR and 
western blotting (Figures 2.3A and B and data not shown). Three major clusters of BMP-
responsive genes were identified based on their patterns of expression (Figure 2), suggesting 
that independent pathways for gene activation by BMPs exist in ECs. In this screen, we 
found angiogenesis-associated genes that participate in intracellular and extracellular 
signaling and matrix reorganization, indicating a coordinated program to allow vessel 
assembly and maturation, including Cox2, Wnt2, Timp1, Adamts1 and Adamts5. An 
independent microarray study in our laboratory also found that Wnt2 is enriched in flk1+ 
differentiated embryonic stem cells and that this Wnt signaling pathway plays a critical role 
in the regulation of angiogenesis 233. The present studies indicate that BMP6 is likely to be 
upstream of Wnt2 expression in the cascade of blood vessel growth, an observation that will 
be helpful to establish network relationships of different signaling pathways in angiogenesis. 
Our analyses indicate that Cox2 is indeed a bona fide transcriptional target of the 
BMP-responsive signaling pathway. Cox2 mediates the biosynthesis of PGs from 
arachidonic acid, and the expression of Cox2 is upregulated by cytokines, including VEGF 
and IL-1β 234. Increased Cox2-dependent PG generation plays diverse roles in increasing cell 
proliferation 235, inhibiting apoptosis 236, and stimulating angiogenesis 237,238. The present 
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 results suggest that the role of Cox2 in angiogenesis in vivo may be due in part to its 
induction by BMPs acting on the vascular endothelium to alter prostanoid generation. 
We have identified in these studies a heretofore-uncharacterized BMP-responsive 
enhancer located at –8147 bp upstream from the Cox2 transcription start site (Figure 2.5). A 
number of transcription factors and signaling events have been previously linked to Cox2 
transcriptional activation; for example, VEGF induces Cox2 upregulation through p38 
MAPK and JNK signaling pathways 232, and Wnt signaling increases Cox2 transcription via a 
β-catenin-dependent pathway that activates the Cox2 promoter through a Tcf-4-binding 
element 217. In osteoblasts, BMP2 activates Cox2 transcription via a specific binding site on 
the Cox2 promoter for core-binding factor activity 1 (cbfa1) 218; however, our data indicate 
that the induction of Cox2 by BMP6 follows different rules, at least in ECs, and these 
experiments provide the first link between Smad activation and Cox2 transcriptional 
regulation. Based on our analyses, we also predict the involvement of the EC-specific 
transcriptional factor GATA2 in BMP6-mediated Cox2 induction, since a GATA rich 
sequence is adjacent to the Smad-binding site (data not shown). Additional reporter studies 
are being performed to clarify the relationship among these angiogenic transcription factors 
in the regulation of Cox2 in ECs. 
Results from in vitro EC function assays including proliferation, migration, and tube 
formation clearly show that Cox2 activity is required for BMP6-induced EC activation 
(Figure 2.6). In addition, pharmacological and genetic disruptions of Cox2 activity indicate 
that BMP6-activated microvessel outgrowth also requires Cox2 activity (Figure 2.7). At the 
same time, the inhibition of Cox1 does not attenuate angiogenesis stimulated by BMP6. 
Given the remarkable structural and kinetic similarity between these two enzymes, our 
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 findings are consistent with other observations that Cox2, but not Cox1, plays an important 
role in mediating angiogenesis under both physiological and pathological situations 211,230. 
Coupled with our own conclusions, this suggests that angiogenesis-promoting prostanoid 
generation in ECs must occur in a precise spatiotemporal fashion to activate the program of 
blood vessel growth. Remarkably, inhibition of Cox2 by NS398 reduces BMP6 mRNA and 
protein expression in bone cells 239. This suggests that positive feedback loops may exist in 
the BMP6 and Cox2 pathway, and such an interaction could play an important role in 
amplifying the activation of ECs by BMP6. Taken together, these studies provide further 
support for the consideration of pharmacological Cox2-targeting strategies to modulate new 
vessel formation in diseases in which angiogenesis is a major component including cancer 
and cardiovascular disease. 
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 Figure legends 
FIG. 2.1. BMP6 induces the upregulation of Id1 in a time-dependent fashion. RT-PCR 
analysis of Id1 in MEC treated with or without BMP6. Total RNA was extracted from MECs 
collected at 4, 12, and 24 h after BMP6 treatment. GAPDH was used as a loading control. 
 
FIG. 2.2. Hierarchical clustering of BMP6 target genes. Differentially expressed genes 
were selected with a p value ≤ 0.05 and ratio fold change ≥ ±1.5, and were subjected to 
hierarchical cluster analysis. Median-centered clusters were viewed with JavaTreeView. Fold 
change relative to common reference is indicated by red (+1.5, full scale) and green (-1.5, 
full scale) intensity. (A) Global view of the clustered genes. (B) Detail of the clustered genes 
with selected genes labeled. Cluster 1 corresponds to genes in Table 1, and cluster 2 
corresponds to genes in Table 2. The complete data set is accessible online through the UNC 
Microarray Database (http://genome.unc.edu). 
 
FIG. 2.3. RT-PCR and Western blotting analysis of gene expression in BMP6-induced 
EC activation. (A) RT-PCR analysis of Wnt2, Cox2, Timp1 and Adamts1 expression using 
total RNA from MECs collected at 0, 4, 12, and 24 h after BMP6 treatment. GAPDH was 
used as a loading control. (B) Western blot analysis of Cox2 protein expression after BMP6 
stimulation for the indicated times. β-actin was used as a loading control. 
 
FIG. 2.4. Elevated levels of secreting prostaglandins derived from Cox2 after BMP6 
stimulation. MECs were pretreated with NS398 (10 μM), SC560 (100 nM) or vehicle before 
BMP6 (100 ng/ml) treatment. Cox2-dependent prostanoid generation was determined by 
measurement of the major forms of PGs generated by ECs, PGE2 (A) and 6-keto-PGF1α (B) 
after 4 h of stimulation in the presence of exogenous arachidonic acid (2.5 μM). Data are 
expressed as mean ± SEM of 6 replicates. 
 
FIG. 2.5. Activation of the Cox2 promoter by BMP signaling. (A) Depiction of 4 
luciferase reporters of the Cox2 promoter, -8653 to +53 bp, -7444 to +53bp, -1500 to +1 bp, 
and –371 to +70 bp. Putative Smad-binding sites are denoted. (B) MECs were transfected 
with luciferase reporter plasmids carrying different lengths of the Cox2 promoter in the 
presence or absence of BMP6 treatment or the cotransfection of an active Smad1 expression 
vector. After 48 h, cells were lysed to measure luciferase activity. Luciferase activity was 
normalized using Renilla luciferase activity. Data shown are the mean ± S.D. of triplicates. 
(C) An end-labeled fragment containing the 29-bp Smad-responsive region was incubated 
with nuclear extracts from MECs and with different non-labeled competitors. Complexes 
were resolved on a nondenaturing 4% polyacrylamide gel followed by autoradiography of the 
dried gel. The addition of nuclear extract produced a specific shifting band denoted as I. The 
asterisk represents a nonspecific band. S: specific; NS: non-specific; SBE: Smad-binding 
element. (D) Nuclear extracts were extracted from MECs treated with BSA or BMP6 or 
cotransfected with Flag-Smad1 and Flag-Smad4.  Overexpression of Smads induced a slower 
migrating complex labeled as II. 
 
FIG. 2.6. Inhibiting Cox2 activity attenuates BMP6-induced MEC proliferation, 
migration and tube formation. (A) Time-dependent response of MEC proliferation to 
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 BMP6 (100 ng/ml) treatment. MEC were pretreated with NS398 (10 μM), SC560 (100 nM), 
or vehicle before treatment with BMP6. Cells were counted at each time point. (B) MEC cell 
migration on gelatincoated filters to BMP6 was assayed after pre-treatment with NS398, 
SC560, or vehicle.  After 6 hours, transmigrated cells were counted. (C) MECs were plated 
on Matrigel-coated 24-well plates, followed by treatment with BMP6, NS398, SC560 and/or 
vehicle. Images were taken 6 h after incubation. Original magnification, 10X. (D) The mean 
and SD of 3 replicate wells of a representative experiment is shown. The p-value was 
determined by Student's t test. 
 
FIG. 2.7. The proangiogenic activity of BMP6 is blocked by Cox2 inhibition in a mouse 
aorta ring assay. (A) Mouse aorta rings (n = 4) were embedded in collagen gel in the 
presence of vehicle, BMP6, NS398, or SC560. Neovessel sprouts were blindly counted at 
Day 6. Original magnification, 4X. (B) Quantitative analysis of aortic ring assays. Columns 
indicate mean of triplicates. Bars indicate SD. Similar results were obtained in a second 
independent experiment. (C) Aortas from Cox2 +/+ and -/- mice were tested in this 
neoangiogenic assay. Images of microvessel outgrowth from aorta with or without BMP6 
treatment are presented. (D) Statistical data of aortic ring assay using Cox2 -/- mice. 
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FIG. 2.1. BMP6 induces the upregulation of Id1 in a time-dependent fashion. 
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FIG. 2.2. Hierarchical clustering of BMP6 target genes. 
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FIG. 2.3. RT-PCR and Western blotting analysis of gene expression in BMP6-induced 
EC activation.  
 41 
  
 
 
FIG. 2.4. Elevated levels of secreting prostaglandins derived from Cox2 after BMP6 
stimulation.  
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FIG. 2.5. Activation of the Cox2 promoter by BMP signaling. 
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FIG. 2.6. Inhibiting Cox2 activity attenuates BMP6-induced MEC proliferation, 
migration and tube formation. 
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FIG. 2.7. The proangiogenic activity of BMP6 is blocked by Cox2 inhibition in a mouse 
aorta ring assay. 
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CHAPTER III 
 
Functional Importance of Bmper in Multiple Organogenesis Determined by in vivo 
Deletion Studies 
ABSTRACT 
Targeted deletion of Bmper encoding an extracellular regulator of BMP signals 
results in perinatal lethality and skeletal deformation.  Bmper transcripts, which are 
represented by knock-in GFP expression, were detected in lung mesenchyma and ventricular 
cardiomyocytes at perinatal stage.  Loss of Bmper activity caused a delayed lung branching 
morphogenesis with condensed alveoli separated by thicken mesenchyme.  In vitro 
cardiomyocyte assays revealed a pro-hypertrophy activity of BMP2.  In addition, 
cardiomyocytes lacking endogenous Bmper were larger in size even in the absence of 
pharmacological induced hypertrophy.  Real-time PCR showed upregulation of cardiac 
differentiation markers and Bmp signaling components in both BMP2 treated wild-type cells 
and Bmper mutants.   This result suggests that Bmper serves as an anti-hypertrophy factor by 
attenuating BMP activity.  The phenotypes associated with Bmper deficiency reveals Bmper 
as a potential therapeutic target in both physiologic and pathologic events in which BMP 
signaling is involved. 
 
 INTRODUTION 
BMP-binding endothelial precursor-derived regulator (Bmper) was first found 
enriched in a fetal liver kinase 1(Flk1)-positive population of differentiating mouse ES144.  
Bmper encodes a protein that has 5 cysteine-rich (CR) von Willebrand C-like domains, 
similar to several BMP extracellular antagonists including Chordin. BMPER mRNA 
expression is highest in heart, lung and skin in adults.  The expression pattern of BMPER in 
developing embryos is highly dynamic.  At E10.5, in situ hybridization revealed Bmper 
expression in two important early angiogenesis regions, the yolk sac where BMP2, BMP4 
and BMP6 activity has been found184, and the aorto-gonadal-mesonephric (AGM) region, 
which contains EC cell precursors and where a high level of BMP4 is found185.  At E14.5, 
Bmper expression is detected in cartilages of the developing skeleton including vertebral 
bodies, ribs, and in the lung mesenchyme183,241. 
Studies show evidence supporting both anti- or pro-BMP activity for Bmper.  For 
example, ectopic expression of Bmper dorsalizes Xenopus embryos144,186.  Bmper inhibits 
BMP-induced osteoblast and chondrocyte differentiation in vitro187.  Bmper inhibits BMP4-
dependent activity in both reporter assay and ES cell differentiation system144.  Other studies 
are consistent with Bmper having a pro-BMP effect.  Bmper activity is important for the 
formation of cross-veins in fly wing 188,189,190,191. Bmper enhances phosphorylation of Smad1 
stimulated by BMP4 in COS7 cells 192.  Injection of both BMPER and BMP4 RNA in animal 
caps synergistically induces the expression of the mesoderm marker, Xbra 186.  A hypothesis 
by Hammerschmidt’s group suggests that Bmper activity is dependent on its proteolytic 
processing; uncleaved Bmper is anti-BMP whereas cleaved Bmper is pro-BMP because only 
uncleaved Bmper can bind to the extracellular matrix193.  
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 To clarify the exact function of Bmper in embryonic development and its role in BMP 
pathway, I performed in vivo targeted deletion of Bmper.  The expression pattern of Bmper in 
lung and heart has been further characterized using a knock-in GFP encoding cassette under 
control of the Bmper promoter.  Bmper null mice exhibit perinatal lethality and defects in 
development of the skeleton, lung, and heart.  Targeted deletion of Bmper in lung resulted in 
defects in branching morphogenesis and increased mesenchymal tissues. Cardiomyocytes 
with Bmper deficiency undergo hypertrophy and display elevated BMP pathway activity.  
These data demonstrate the importance of Bmper in balancing BMP signaling and regulating 
organogenesis. 
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 METARIALS AND METHODS 
Reagents 
Phospho-Smad1/5/8 antibody was purchased from Cell Signaling. Thyroid 
transcription factor 1 (TTF1) antibody was the product from GeneTex, Inc.  Anti pro-
surfactant C (pro-SPC) antibody and anti calcitonin gene-related peptide (CGRP) were kind 
gift from Dr. Jeffrey Whitsett.  Anti-Clara Cell Secretory Protein (CCSP) and anti-SPB were 
from Upstate. 
Target deletion of mouse BMPER gene 
Mice with Bmper deficiency were generated with standard gene targeting methods242. 
The targeting construct was generated by using pOSfrt 243 as the backbone, which contains (i) 
a 4.4-kb PCR-generated fragment from genomic DNA that includes the BMPER promoter; 
(ii) a 700-bp cDNA encoding EGFP (CLONTECH); (iii) a 300-bp bovine growth hormone 
poly(A) addition region; and (iv) a 2.0-kb PCR-generated genomic fragment from second 
intron of the BMPER gene. Embryonic stem (ES) cells (129/ ola) were electroporated with 
the target construct. ES colonies, which were G418/ganciclovir-resistant, were identified by 
the PCR-based assay.  Homologous recombination was confirmed by Southern analysis using 
both 5’ and 3’, diagnostic probes.  The targeted ES cells were injected into C57BL/6 
blastocysts242.  Male chimeras were mated to wild-type C57BL/6 females to establish an 
isogenic line, and all experiments were conducted on the resulting hybrid background. 
Genotyping of BMPER mutant mice 
Genomic DNA of BMPER deficient mice were isolated and digested with HpaI (5’ 
probe) and NheI (3’ probe) to identify wild-type 240 and targeted alleles.  BMPER 
homologous mutants were generated by timed heterozygous matings.  A PCR analysis has 
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 been developed to genotype the embryos and pups.  PCR samples were denatured in 95°C for 
60 sec then subjected to 35 cycles of three step amplification, a 30-sec 94°C denaturation, 
30-sec 68°C annealing and 45-sec 72°C extension step.  A 608-bp product (primers berwtf 
and bergtr) represents the WT allele and a 455-bp (primers berkof and bergtr) product 
indicates the target allele.  PCR primers: berwtf: 5’-
CTGCATCCACCCCTGTAAGTTTCTAG-3’;  
berkof: 5’-GTCCTCTGATGGTCAAAGTCCTG -3’;  
bergtr: 5’-CCAAGCCCAACGCTCCCTGCTGAAATCC-3’. 
Southern blotting analysis 
Southern blotting analysis was carried out as previously described (Matzuk et al., 
1992). Genomic DNA was digested with either HpaI or NheI and electrophoresed in a 1% 
agarose gel.  Both 5’ and 3’ probe was labeled with [α-32P] deoxycytidine triphosphate by 
random oligopriming.  Membranes containing DNA have hybridized with labeled probes in 
65°C for one hour.  The locations of radioactive probe hybridization on membrane were 
detected by autoradiography. 
Immunohistochemistry  
Mouse tissues were fixed overnight in 4% paraformaldehyde/phosphate buffered 
saline (PBS), dehydrated in a series concentration of ethanol, paraffin embedded and 
sectioned at 5 μm. Immunohistochemistry was performed as described.  Sections were first 
deparaffinized by xylene and rehydrated in graded ethanol series.   Slides have been 
incubated for 15 min with Antigen unmask reagent (Vector Laboratories, Burlingame, CA) in 
coplin jar in steamer for antigen retrieval. Blocking was achieved with 2.5% horse serum for 
10 min.  Primary antibody incubations were performed for 30 min at room temperature (RT).  
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 Biotinylated secondary antibodies (Vector Laboratories) were added to sections for 10 min, 
followed by signal detection using Vector NovaRED reagent (Vector Laboratories).  
Embryonic Mouse Cardiomyocytes Isolation and hypertrophy study 
Mouse Cardiomyocytes were prepared from hearts of E 18.5 embryos using a 
commercially available cardiomyocyte isolation kit (Worthington Biochemical) as previously 
described244.  Hearts were minced and incubated with trypsin and collagenase in 37 ºC 
overnight.  To reduce the total numbers of fibroblasts, cells were first preplated on untreated 
plastic flasks for 1 hour.  Nonadherent portion of cells, which were enriched for 
cardiomyocytes, were cultured in minimum essential medium 245 containing Earle’s salt with 
glutamine and 10% horse serum and 5% FBS. Cells were plated on laminin-coated tissue 
culture plates at a density of  1x105 cells/cm2 and grown at 37°C in 5% CO2. Cells were 
cultured for 48 hours before starting the experiments.  After overnight serum starvation, cells 
were treated with control vehicle, BMP2 (100 ng/ml), and PE (100 μM) for 48 hrs.  
Cardiomyocytes were labeled with anti-β myosin heavy chain (βMHC) and florescent images 
were taken for measurement.  
RNA isolation and real-time PCR 
Total RNA was extracted from cells and tissues by using RNeasy Kits (Qiagen, 
Valencia, CA). The RNA isolation was performed according to the manufacturer’s 
instructions.  First-stand cDNA was synthesized using 500 ng of total RNA with 200 U of 
Superscript II RNase H-RT (Invitrogen) in a final volume of 20 μl.  The resulting products 
were then treated with RNase A for 30 min at 37°C and purified thereafter with Qiaquick 
PCR purification kit (QIAGEN, Mississauga, Ontario).  Realtime PCRs were carried out 
using 7500 Real-time PCR system (Applied Biosystems, Foster City, CA). 
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 RESULTS 
Deletion of BMPER by homologuous recombination.  
Based on the expression and functional studies, we hypothesized that the regulatory 
role of Bmper on BMP signals could be very important in embryonic development, 
especially in the early steps in blood vessel formation. Since Bmper expression is first 
detected at E 7.0 (mid-gastrulation)183, Bmper null embryos are expected to survive until at 
least that stage.  For these reasons, a targeting deletion of Bmper in mice has been designed 
to characterize the exact role of Bmper in vivo. I made a targeting construct for generating 
Bmper-/- mice (Figure 3.1A).  The targeting vector contains a green fluorescent protein 
(GFP) expression cassette and a neomycin resistance marker under the control of the MC1 
promoter. Thymidine kinase (TK) encoded in the targeting vector is used for counterselection 
against nonhomologous integration.  Mouse 129/Ola ES cells were transfected with the target 
vector in collaboration with the UNC Animal Models Core Facility.  Homologous 
recombination of ES cells was first selected by growing cells in G418 and gancycolvir, 
followed by PCR screening and Southern blotting using 5' and 3' probes with HpaI and NheI 
as the diagnostic enzymes (Figure 3.1B).  Targeted ES clones were microinjected into the 
blastocysts derived from C57Bl/6 embryos and implanted into pseudo-pregnant recipient 
females to create chimeras.  Chimeras with targeted BMPER deletion and GFP knock-in were 
first mated with C57Bl/6 wild-type mice to generate heterozygous (HT, +/-) mice.  Pups were 
genotyped with two pairs of primers, one for the WT allele and the other for the targeted 
allele.  HT mice were mated to create BMPER-/- mice with a mixed C57Bl/6 and 129/Ola 
background.  BMPER-/- mice were confirmed by PCR and southern blotting (Figure 3.1C).  
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 The amount of Bmper transcript in hearts and lungs of control and mutant pups was 
determined by RT-PCR (Figure 3.1D). 
Perinatal lethality and skeletal defects of Bmper deficient mice.   
Bmper-/- mice died immediately after birth, while WT and HT littermates exhibited 
no lethality (Table 3.1).  At E18.5, BMPER-/- embryos had a reasonable survival rate based 
on Mendelian ratios, even though they had smaller trunks and shorter tails than their WT and 
HT siblings (Figure 3.1E).  No obvious gross defects were observed at E 13.5 except Bmper-
/- embryos had a kink at the tip of their tails (data not shown). 
Expression of Bmper in the lung and heart at perinatal stage.   
Previous in situ and nLacZ-knocked-in data reveal the presence of Bmper in 
developing lung and heart during E10.5 to E14.5183,241.  We observed the distribution of 
Bmper in these two organs at P0 by locating GFP expression (Figure 3.2).  Bmper was 
expressed in lung mesenchymal cells among maturing alveoli.  In heart, ventricular 
cardiomyocytes are the major cell type to express Bmper.   
Lung morphogenesis defects in Bmper mutants.   
Bmper-/- mice were previously shown to have defects in lung maturity241.  Delayed 
lung branching morphogenesis was observed as early as E17.5 (Figure 3.3).   At E18.5, 
Bmper deficient lungs displayed fewer terminal sacs especially in the peripheral region, 
which were separated by thicken interstitial mesenchyme.  Compared with well developed 
lungs from WT siblings, Bmper-/- lungs had smaller terminal sacs due to the lack of alveolar 
expansion at P0 (Figure 3.3).  There is an increased ratio of type II epithelial cells to total 
distal cells in E18.5 mutant lungs according to pro-SPC (type II epithelial cell marker) 
staining (Figure 3.4A and B).  Neuroepithelial bodies formed by pulmonary neuroendocrine 
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 cells (PNEC), which were marked by Calcitonin gene-related peptide (CGRP) were also not 
altered in Bmper null lungs (Figure 3.4A).  At adulthood, HT lungs exhibited reduced 
surfactant production without noticeable decrease in type II cell numbers compared with WT 
ones, while Clara cells, which are CCSP positive, were not affected (Figure 3.4C and data 
not shown).  
Hypertropy phenotype in Bmper deficient cardiomyocytes.   
To investigate the importance of Bmp pathway in cardiomyocyte function, an in vitro 
hypertrophy assay were performed using E18.5 cardiomyocytes isolated from Bmper+/+, +/-
, and -/- embryos.  Each genotype of cells were treated with control vehicle, Bmp2 (100 
ng/ml), and PE (100 μM).  A total of 100 cells per condition were measured for surface size.  
As expected, PE induced about a 30% cell size increase in WT cells, while Bmp2 stimulated 
cells were almost 2 times larger than control cells (Figure 3.5A and B).  Bmper deficient cells 
underwent hypertrophy without any treatment and were unresponsive to Bmp2 or PE induced 
hypertrophy (Figure 3.5A and B). 
Upregulation of cardiac markers and BMP signaling molecules in Bmper null 
cardiomyocytes.   
The mechanism of hypertrophy induced by BMP2 and Bmper deficiency was further 
characterized at the transcriptional level.  Several cardiac markers and specific transcriptional 
factors including atrial natriuretic factor (ANF), αMHC, smooth muscle actin 246, Tbox5, and 
GATA4, were examined by real-time PCR.  Both BMP2- and PE-induced WT cells had 
higher expression levels of these factors compared to cells under control condition (Figure 
3.6A).  Bmper -/- cells had elevated mRNA levels of cardiac specific markers despite 
treatments (Figure 3.6A).  The expression of different components in the BMP pathway was 
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 also assessed.  BMP2 and PE positively regulated BMP signals by transcriptionally increase 
of BMP ligands, receptors, and R-Smads, which also induce the upregulation of I-Smads, 
Smurf1, and Noggin due to a negative feedback (Figure 3.6B, C, and data not shown).  On 
the other hand, Bmper-null cells showed an elevated activity of BMP pathways even under 
basal conditions (Figure 3.6B and C).  These results suggest that Bmper protects 
cardiomyocytes from hypertrophy through modulation of BMP signals. 
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 DISCUSSION 
Our in vivo targeted deletion studies showed that Bmper is involved in multiple 
organogenetic processes and that its function is important for survival during the perinatal 
stage (Table 3.1).  Since BMP pathways are well known as positive regulators for bone 
development, the skeleton malformation observed in our Bmper null embryos, similar to an 
independent knock-out study241, are consistent with the pro-BMP activity of Bmper (Figure 
3.1D).   
The GFP staining pattern revealed the distribution of Bmper transcripts in the lung 
and heart at P0 (Figure 3.2A and B).  Bmper expression was restricted to the lung 
mesenchyme from the onset of development (E10.5)183,241 to P0 (Figure 3.2A).  In the heart, 
Bmper was mainly expressed in ventricular cardiomyocytes and in the floor of left atrium 
(Figure 3.2B and data not shown).  Double immunostaining with GFP and specific cell 
markers will be performed to further distinguish cell types expressing Bmper.  Similar 
approaches will also be used on earlier stages of embryos and adult mice to demonstrate 
dynamic Bmper expression during development. 
Bmper-/- lungs display an immature phenotype including delayed lung branching 
morphogenesis and smaller alveoli surrounded by abundant mesenchyme (Figure 3.3).  Most 
lines of evidence (described in chapter I) suggest that BMP signals are involved in promoting 
the proliferation and survival of distal epithelial cells, rather than in regulating their 
differentiation157,158.  Our data were consistent with these studies and showed an increased 
population of type II epithelial cells in E18.5 mutant lungs compared to WT ones (Figure 
3.4A and B).  Increased numbers of both epithelial and mesenchymal cells in Bmper deficient 
lungs support this model (Figure 3.7) that Bmper negatively regulates the proliferation and 
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 survival of cells by antagonizing BMP4 activity.  In this model, BMP4, which is secreted by 
distal epithelial, increases proliferation and reduces apoptosis.  This activity is attenuated by 
Bmper released from surrounding mesenchyme.  There is an overall pro-proliferation and 
anti-apoptosis effect on epithelium because of relatively high concentration of BMP4 and 
lower level of Bmper.  In mesenchyme, an opposite effect is caused by the reverse 
concentration distribution of BMP4 and Bmper.  More experiments will be performed to test 
this hypothesis.  The difference in the apoptosis and proliferation between Bmper null lungs 
and controls will be analyzed by Tunel assay and the expression level of apoptotic related 
genes and cell proliferation factors will also be examined by real-time PCR and western 
blotting.  This model will be further supported if the lung phenotype of Bmper null mice is 
relieved by crossing them with mice having conditional deletion of Alk3 or Bmp4 in lungs159.  
We have also observed a decreased surfactant synthesis in adult mutant lungs compared with 
WTs (Figure 3.4C).  This suggests that Bmper may play an important role in maintaining the 
function of matured type II epithelial cells. 
Our results indicate that both exogenous BMP2 treatment and endogenous Bmper 
reduction in cardiomyocytes stimulates hypertrophy (Figure 3.5A and B).  Activation of the 
BMP pathway results in the upregulation of cardiac specific markers including ANF, SMA, 
and GATA4 (Figure 3.6A).  In vitro studies show that Bmp2 can enhance myocardin 
transactivation activity to increase cardiac gene expression247.  Myocardin serves as a 
cofactor for the serum response factor (SRF) pathway and overexpression of myocardin 
induced cardiomyocyte hypertrophy and upregulation of cardiac markers248.  Further analysis 
of myocardin activity in BMP2 treated cardiomyocyte will be helpful to clarify the 
relationship between these two pro-hypertrophy signals.   
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 We also observed that the reduction of Bmper in cardiomyocytes led to elevated 
levels of BMP signaling, which in turn induced hypertrophy even without the addition of 
BMP2 (Figure 3.5 and 3.6).  This indicates that Bmper has anti-hypertrophy activity, which 
is dependent on its inhibition of BMP signals in cardiomyocyte.  To test this hypothesis, we 
will repeat the in vitro hypertrophy study by utilizing recombinant Bmper protein and a 
BMP2 neutralizing antibody (R&D Systems).  If Bmper acts as an antagonist of BMP 
signaling in cardiomyocytes, we should observe that the treatment of Bmper or the BMP2 
blocking antibody will both inhibit BMP2 induced hypertrophy and rescue the mutant 
phenotype. 
As previously described in the introduction, the BMP pathway is very important in 
early cardiac development especially in both cushion and valve formation.   The in vitro 
study described here also shows that Bmper deficient cardiomyocytes display a hypertrophy 
phenotype.  Several in vivo experiments will be performed to characterize the cardiac 
function in Bmper+/- mice compared with their WT littermates.  First, echocardiography will 
measure the thickness of ventricular walls, the valvular regurgitation, and the cardiac output 
in both WT and mutant mice at basal condition.  The hypertrophy phenotype can be induced 
using aortic banding, which is well established in our lab249.  If mutant mice show more 
severe cardiac enlargement after the surgery, this will further support that Bmper protects 
heart from stress induced hypertrophy by antagonizing BMP activity. 
Based on our observations of Bmper null mice phenotypes, the pro- or anti-BMP 
activity of Bmper are tissue specific.  Earlier studies indicated that Bmper’s effect on BMP 
signals relies on its proteolytic form and Bmper can also compete with Chordin for binding 
to BMP ligands193.  Tissue specific expression pattern of BMP antagonists and/or the 
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 unidentified proteinase, which cleaves Bmper, may be the reason for the complicated action 
of Bmper on BMP signaling.  A microarry analysis on mouse embryonic fibroblasts (MEFs) 
isolated from control and Bmper mutant embryos were recently performed by Rusty Kelley 
in our lab.  These data will be helpful in elucidating the exact regulatory role of Bmper on the 
BMP pathway. 
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 FIGURE LEGENDS 
FIG 3.1. The targeted deletion for the Bmper gene in ES cells and in mice. (A) Strategy 
for targeted deletion of Bmper gene.  Homologous recombination between the targeting 
vector and the endogenous Bmper gene in the mouse ES cell results in the deletion of Exon 1 
and 2 and the insertion of GFP expression cassette.  (B) Southern blot analysis of DNA 
isolated from targeted ES clones, B6 and D10. WT, wild type.  (C) Southern blot genotyping 
confirmed the targeted deletion of first two exons in Bmper.  DNA was extracted from 
littermates of heterozygous matings at P0.  (D)  RT-PCR showed that Bmper mRNA levels 
were reduced or depleted in lungs and hearts from P0 mutants.  GAPDH was used as 
endogenous control.  (E) External morphology of Bmper nulls embryos at E18.5.  From left 
to right, Bmper+/+, +/-, and, -/-.   
 
FIG 3.2.  Expression of Bmper in lungs and hearts observed with GFP staining at P0.  
(A) Bmper is expressed in lung mesenchymal cells.  GFP staining was only observed in 
mutant tissues and WT lungs were used as a negative control.  Positive staining is brown and 
count staining is blue.  Arrows, GFP-positive cells.  (B) Bmper expression is detected in 
ventricular cardiomyocytes in HT heart.  Scale bars: 100 μm.  Magnification, x 40 (insets in 
lower panel). 
 
FIG 3.3.  Lung morphogenesis defects in Bmper mutants during later embryonic and 
perinatal stages.  HE staining of lungs from WT, HT, and KO lungs at E17.5, E18.5, and 
P0.  Bmper-/- lungs showed delayed branching morphogenesis and inadequate expanded 
alveoli, which were separated by overgrowing interstitial mesechyme.  Scale bars: 100 μm. 
 
FIG 3.4.  Increased type II epithelial cells in Bmper null lungs at perinatal stage and 
decreased surfactant synthesis in adult mutant lungs.  (A) Pro-SPC and CGRP staining of 
control and mutant lungs at E18.5.  The number of type II epithelial cells were increased in 
mutant lungs, while PNECs, CGRP positive cells were unaltered.  Arrows, pro-SPC and 
CGRP positive cells.  Scale bars: 50 μm.  (B) Statistical analysis of type II cells ratio to total 
cells.  Four random fields on slides were chosen for each genotype.  *p<0.01; **p<0.05 
determined by Student t-test.  (C) Pro-SPC, SPB, CCSP staining of adult lungs.  Reduced 
intensity of pro-SPC and SPB staining indicates decreased surfactant synthesis in HT lungs.  
Clara cells, which were labeled by CCSP, were not affected by Bmper deficiency.  Arrows, 
pro-SPC, SPB, and CCSP positive cells.  Scale bars: 100 μm.  Magnification, x20; x40 
(insets). 
 
FIG 3.5.  Cardiomyocyte hypertrophy induced by Bmper deficiency.  (A) Immuno-
florescent staining of cardiomyocytes with βMHC.  Cardiomyocytes were isolated from 
E18.5 control and mutant embryos.  Cells were serum starving overnight and treated with 
control, BMP2 (100 ng/ml), and PE (100 μM) for 48 hours.  (B) Statistic analysis of 100 cell 
surface measurement for each genotype and treatment is shown. The p-value was determined 
by Student's t test.  *p<0.001. 
FIG 3.6.  Elevated expression level of Cardiac markers and BMP pathway components 
in Bmper null cardiomyocytes.  Real-time PCR analysis of BMP ligands (A), receptors and 
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 R-smads (B), and I-smads and Noggin (C) in WT and KO cardiomyocytes.  RNA were 
isolated from cardiomyocyted treated with control vehicle, BMP2 (100 ng/ml) and PE (100 
μM) for 48 hours.  The p-value was calculated by Student’s t test. *p<0.001, **p<0.05. 
 
FIG 3.7. Schematic model of BMP signaling and Bmper activity in distal embryonic 
lung.  Epithelium releases BMP4 to promote the proliferation and reduce apoptosis, while 
mesenchyme secretes Bmper to inhibit BMP signals, which in turn causes decreased 
proliferation and enhanced apoptosis.  Alk3 is expressed by both epithelial cells and 
mesenchymal ones and mediates BMP downstream effect in both tissues.  Activation of BMP 
signaling is dependent on the different concentration ratio of BMP4 and Bmper locally. 
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FIG 3.1. The targeted deletion for the Bmper gene in ES cells and in mice. 
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FIG 3.2.  Expression of Bmper in lungs and hearts observed with GFP staining at P0.   
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FIG 3.3.  Lung morphogenesis defects in Bmper mutants during later embryonic and 
perinatal stages. 
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FIG 3.4.  Increased type II epithelial cells in Bmper null lungs at perinatal stage and 
decreased surfactant synthesis in adult mutant lungs.   
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FIG 3.5.  Cardiomyocyte hypertrophy induced by Bmper deficiency.   
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FIG 3.6.  Elevated expression level of Cardiac markers and BMP pathway components 
in Bmper null cardiomyocytes.   
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FIG 3.7. Schematic model of BMP signaling and Bmper activity in distal embryonic 
lung.   
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CHAPTER IV 
CONCLUSION AND FUTURE PLANS 
We investigated the role of the BMP signaling during development.  Our in vitro 
studies identified an important BMP downstream target, Cox2, which mediates BMP6-
induced EC activation in angiogenesis.  In vivo deletion of a BMP extracellular regulator, 
Bmper, highlights the importance of BMP signaling in several organogenetic processes, 
including the development of the skeleton, lung, and heart. 
Transcriptional activation of Cox2 promoter by BMP6 and other signals 
Our reporter assays identified a SBE site in the Cox2 promoter region (Figure 2.5).  
The Cox2 promoter contains multiple transcriptional factor binding sites, including a cAMP-
responsive element (CRE), nuclear factor interleukin-6 (NF-IL6) and nuclear factor κB 
(NFκB) elements250-252.  The CRE binding site is important in response to the stimulation of 
src and ras in epithelial cells253,254.  NFκB and NF-IL6 elements are crucial sites for 
transcriptionally regulation of Cox2 by lipopolysaccharide and endotoxin in macrophage-like 
cells255-257.  These promoter elements show redundancy in endotoxin response macrophage 
lineage258.   In addition, BMP2 activates Cox2 transcription via a cbfa1 binding site on the 
Cox2 promoter in osteoblasts 218.  The Wnt pathway also transcriptionally upregulates Cox2 
through a Tcf-4-binding element217.  To find out whether other existing elements participate 
in BMP6-induced Cox2 upregulation, we propose to perform reporter assays using luciferase 
constructs with different combinations of mutant binding sites.  If mutation of a certain 
 
 binding site(s) affects the BMP6-induced luciferase activity, we can identify which 
element(s) may be important for the upregulation of Cox2 by BMP6.  Results from this assay 
can also be helpful for characterizing the crosstalk among BMP signaling and other growth 
factors such as VEGF and Wnt, which use Cox2 as a common downstream mediator.  
Cox2-dependent PG synthesis in BMP6-mediated angiogenesis 
Our in vitro data indicate that Cox2, instead of Cox1, mediates downstream effects in 
BMP6-induced angiogenesis.  This finding is consistent with previous studies showing 
functional difference between these two enzymes, in spite of a 61% amino acid sequence 
homology211,230,259.  Two mechanisms contribute to their different roles in physiological and 
pathological events.  First, the Cox1 promoter lacks a TATA or CAAT box while the Cox2 
promoter contains multiple transcriptional regulatory elements 259,260.  These features allow 
Cox1 to be a constitutive expressed enzyme whereas Cox2 expression is inducible, upon 
stimulation of multiple cytokines and growth factors.  Second, the two isoforms of Cox 
exhibit different preferential functional coupling with prostaglandin synthases261.  In the case 
of PGE2 synthesis, Cox1 preferentially couples with cytosolic prostaglandin E synthase 
(cPGES), which is constitutively expressed to maintain PGE2 production required for cellular 
homeostasis 262. Cox2 selectively cooperates with an inducible microsomal prostaglandin E 
synthase-1 (mPGES-1) to increase PGE2 production under the induction of cytokines and 
growth factors 263.  The upregulation of both Cox2 and mPGES-1 by IL-1β suggests that the 
coregulation of these two enzymes may be important for the increased production of PGE2 by 
IL-1β stimulation 264,265.  To find out whether mPGES-1 is also upregulated by BMP6, the 
expression of mPGES-1 in BMP6-induced ECs can be examined by RT-PCR, Western 
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 blotting.  Once we confirm that the upregulation of mPGES-1 is at transcriptional level, the 
promoter region of mPges-1 will be further examined by reporter assays.  
BMP-induced Cox2 activity in cardiovascular diseases and tumorigenesis  
 The nonspecific non-steroidal anti-inflammatory drugs (NSAIDs) have been widely 
used in treating various inflammatory related diseases.  One of the most common side effects 
is gastrointestinal (GI) syndrome, which is caused by the disruption GI integrity maintained 
by Cox1 266.  Cox2 selective inhibitors have been used to reduce GI adverse events, but these 
drugs have increased the risk of cardiovascular disease compared with nonspecific inhibitors 
267,268.  This may be related to differences in expression and product synthesis of the two Cox 
isoforms in vasculature.  Cox1 is the predominant form in platelets and mediates the 
synthesis of TXA2, which is a vasoconstrictor and positive regulator for platelet aggregation, 
whereas Cox2 is involved in producing PGI2, which is a vasodilator and inhibitor of platelet 
aggregation 269,270. Unlike the nonspecific inhibitors, which block production of both PGI2 
and TXA2, Cox2 inhibitors selectively reduce production of PGI2 by ECs without 
suppression of Cox1-derived TXA2 271.  The unbalance in biosynthesis between PGI2 and 
TXA2 results in drug-induced thrombosis, which is related to an increased incidence of 
cardiovascular diseases 272.  Our data demonstrates that BMP6 transcriptionally upregulates 
Cox2 in ECs (Figure 2.3 and 2.5) and also increases the biosynthesis of PGI2 and PGE2 
derived from Cox2 (Figure 2.4).  These findings suggest that BMPs can be used to reduce the 
risk of cardiovascular incidence related to Cox2 selective inhibitors.  Additional 
transcriptional studies need to be conducted in other non-EC cell lines to test whether BMP6-
induced Cox2 upregulation is restricted to ECs or is pleiotropic. 
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  The pro-angiogenetic activity of Cox2 has been implicated as a promoting factor in 
carcinogenesis and the overexpression of Cox2 has been observed in breast 273 and colorectal 
cancer 274-276.  Inhibition of Cox2 activity by either genetic deletion or pharmacological 
inhibition reduces tumor growth, supporting the idea that Cox2 acts as a positive regulator in 
tumor development 277,278.  At the same time, the BMP signal pathway has also been linked to 
tumorigenesis.  Mutations of Smad4 and Alk3 are found in familial juvenile polyposis 279.  
Alk3 is also mutated in the germ line of some families carrying an inherited type of breast 
cancer, called Cowden syndrome 280.  Both pro- and anti-tumor effects of BMP signaling 
have been reported.  For example, overexpression of BMP6 and BMP7 was detected in 
metastatic prostate cancer cells 281-283.  Conversely, BMP7 is downregulated in 
nephroblastoma 284.  BMP4 and BMP6 transgenic mice show high resistance to 12-O-
tetradecanoyl-phorbol-13-acetate-induced tumorigenesis compared to controls 285,286.  The 
pro-tumorigenesis aspect of BMP signaling in certain tumors may involve increased 
angiogenesis by upregulation of Cox2, demonstrated in our in vitro studies.  A similar 
relationship has also been observed between VEGF and Cox2 in breast cancer, where they 
act synergistically to promote tumor angiogenesis 273.  Our studies suggest that the 
development of a more effective combination therapy, which targets both Cox2 and BMP 
signaling, may be an effective treatment in cancers showing elevated levels of these two 
pathways. 
Tissue specific opposing activities of Bmper 
Data from Bmper null studies reveal tissue specific pro- and anti-BMP activity of 
Bmper.  Two models can be used to elucidate these opposing activities of Bmper (Figure 
4.1).  Firstly, similar to chordin, Bmper is proteolytically cleaved into N- and C-terminal 
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 fragments, which form a heterodimer via disulfide bonds 144,193.  Both uncleaved and cleaved 
Bmper can strongly bind to BMPs, but only the uncleaved form is capable of binding to 
heparin in extracellular matrix 193.  The association of uncleaved Bmper with the extracellular 
matrix sequesters BMPs from their cell surface receptors and inhibits BMP signaling.  The 
proteolytic cleavage releases Bmper from binding with the extracellular matrix and converts 
Bmper from an anti-BMP factor to a pro-BMP regulator.  Both in vitro and in vivo studies 
can be performed to test this model.  MECs can be treated with the control vehicle, BMP6 
alone, BMP6 with the conditional media containing full-length Bmper with mutant cleavage 
site, or BMP6 with the conditional media containing cleaved Bmper fragments.  The activity 
of BMP signaling can be determined by quantifying phospho-Smad1/5/8 and BMP 
downstream targets, including Id1 and Cox2 by real-time PCR and Western blotting.  If only 
the full-length Bmper proteins but not the cleaved fragments are able to inhibit the BMP 
activity and block BMP-induced upregulation of Id1 and Cox2, this will suggest that 
proteolytic cleavage is the main force to switch Bmper from an anti-BMP factor to a pro-
BMP regulator.  To determine the role of Bmper on BMP signaling in specific tissues, the 
expression levels of BMP downstream targets and the amount of phospho-Smad1/5/8 in 
different tissues from Bmper knockout mice and WT ones will first be analyzed.  For 
example, if Bmper is a negative regulator for BMP signaling in a certain tissue, then the 
Bmper deficient tissue should have elevated BMP signaling activity compared with WT.  We 
next can determine the amount of full-length Bmper cleaved in that tissue by Western 
blotting.  Our hypothesis will be supported if the predominant form of Bmper is full-length in 
the tissue that Bmper has an anti-BMP role, while cleaved fragments will be the majority in 
the tissue where Bmper is pro-BMP signaling. 
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 The second model involves clathrin-coated pits (CCPs)-mediated endocytosis.  
Studies showed that BMP receptors (both type I and type II receptors) undergo constitutive 
endocytosis via CCPs 287.  Data from our lab (Rusty Kelley, unpublished data) suggests that 
the presence of Bmper can facilitate the endocytosis of BMP ligands in a cell-type specific 
manner.  This receptor-dependent endocytosis is not required for phosphorylation of R-
Smads, but is essential for transmitting R-Smads into the nucleus where they can regulate the 
transcriptional activity of downstream targets 287.  At the same time, internalized receptors 
either recycle to the plasma membrane, resulting in continual activation, or transport to 
lysosomes for degradation, and therefore attenuating BMP signaling 288.  According to our in 
vitro results (Rusty Kelley, unpublished data), Bmper promotes the degradation of 
internalized BMPs and partially inhibits Smad-dependent downstream signaling through 
endocytosis.  Thus, Bmper exhibits an anti-BMP activity through CCRs-dependent 
endocytosis, which is cell-type specific and could also be tissue specific. 
 
 
FIG. 4.1. Opposing effects of Bmper on BMP pathway dependent either on its cleavage forms 
or CCPs-mediated endocytosis. 
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 Besides these two putative models, Bmper may exhibit its regulatory role in other 
ways.  1) BMP antagonist-dependent model.  Bmper can modulate BMP signals by its 
interaction with other BMP antagonists such as Chordin, Noggin, or Gremlin.  Competitive 
binding assays in vitro reveal that Bmper and Chordin compete for the binding to BMP2 193.  
This competitive binding between Bmper and Chordin provides the possibility that Bmper 
may act as a pro-BMP factor by blocking the interaction of Chordin with BMPs.  More in 
vitro competitive binding experiments need to be done to test if Bmper can similarly compete 
with other BMP antagonists for their binding to BMPs.  2) BMP receptor complex model.  
As described in the introduction, the two forms of the BMP receptor complexs, PFC and 
BISC, determine the activation of either Smad-dependent or independent pathways 143.  Since 
the binding of Bmper to BMPs does not interfere with their interaction with the 
transmembrane receptors 193, this association may affect the preference in binding to the two 
different receptor complexes, favoring one pathway over the other.  To test this hypothesis, 
we can examine the phospho-Smads and the MAPK activity after BMP4 treatment with or 
without co-treatment of Bmper in vitro.  The phospho-Smads and the MAPK activity in 
different tissues of WT and Bmper null mice will also be analyzed to determine the role of 
Bmper in the regulation of Smad-dependent and Smad-independent signaling. 
The role of Bmper in lung and heart development 
The role of Bmper in lung and heart formation has been analyzed using the Bmper 
knockout mice.  We have observed the overgrowth of both epithelial and mesenchymal cells 
in the distal region of Bmper null lung.  We hypothesize that Bmper released from 
mesenchymal tissues negatively regulates the proliferation and survival of cells by 
antagonizing the activity of BMP4 secreted by the epithelium.  To test this hypothesis, the 
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 difference in the apoptosis and proliferation between Bmper null lungs and controls will be 
analyzed by Tunel assay.  The expression level of apoptotic related genes and cell 
proliferation factors will also be examined by real-time PCR and Western blotting.  The anti-
BMP activity of Bmper will be further supported if the lung phenotype of Bmper null mice is 
relieved by crossing them with mice having conditional deletion of Alk3 or Bmp4 in lungs159.   
Our in vitro study shows that BMP2 can induce hypertrophy in WT cardiomyocytes, 
where as Bmper knockout cardiomyocytes display a hypertrophy phenotype without any 
treatment and have an elevated level of BMP signaling.  This indicated that Bmper serves as 
an anti-hypertrophy factor by attenuating BMP activity.  To test this hypothesis, we will 
repeat the in vitro hypertrophy study by utilizing the recombinant Bmper protein and a BMP2 
specific neutralizing antibody (R&D Systems).  If Bmper acts as an antagonist of BMP 
signaling in cardiomyocytes, we should observe that the addition of Bmper or the BMP2 
blocking antibody will both inhibit BMP2 induced hypertrophy and rescue the knockout 
phenotype. 
BMP signaling is involved in early cardiac development especially in both cushion 
and valve formation (described in the introduction).  Bmper plays an important role in heart 
formation through its interaction with the BMP pathway.  Several in vivo experiments will be 
performed to characterize the cardiac function in Bmper+/- mice compared with their WT 
littermates.  First, echocardiography will measure the thickness of ventricular walls, the 
valvular regurgitation, and the cardiac output in both WT and mutant mice at basal condition.  
The hypertrophy phenotype can be induced in vivo by aortic banding, which is well 
established in our lab 249.  If Bmper+/- mice develop more severe ventricular enlargement 
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 and heart failure after the surgery, this will further support that Bmper protects the heart from 
hypertrophy by antagonizing BMP activity. 
Retinal angiogenesis in Bmper deficient mice  
To further characterize the role of Bmper and BMP signals in angiogenesis, we 
propose to adapt an in vivo retinal angiogenesis model to our Bmper heterozygous mice.  We 
have detected the enrichment of Bmper expression in retina (Figure 4.2A), which strongly 
suggests the involvement of Bmper in retinal development.  Normal retinal vessels start to 
form from the central optic disc to peripheral areas during P0 to about P11.  In the following 
two weeks, vascular plexuses are established by sprouting and remodeling289,290.  To 
determine if the reduced Bmper amount leads to abnormal vascular formation, the retinal 
vasculature of WT and Bmper+/- mice at early postnatal (P6) and adult stage will be 
examined by whole-mount isolectin staining (normal P14 retina staining shown in Figure 
4.2B).  Disruption of retinal vasculature either postnatally or during the adult period in 
Bmper deficient mice will demonstrate that Bmper participates in retinal angiogenesis 
through modulating BMP signals. 
 
FIG 4.2. Expression of Bmper and BMPs in retina and whole-mount retinopathy. (A) 
RT-PCR analysis of Bmper and BMP ligands in whole eye and retina from WT adult mice. 
(B) Whole-mount isolectin staining of P14 WT retina. 
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 In addition to studying the influence of Bmper in normal retinal vascular 
development, its effect on hypoxia-driven neovascularization will also be investigated by 
oxygen induced retinopathy (OIR) 291-294.   In this experiment, Bmper+/- pups and their WT 
littermates will be exposed to 75% oxygen from P7 to P12.  The high concentrations of 
oxygen will cause the regression of the capillary network in the center of the retina in WT 
mice.  Pups will be returned to normoxia at P12.  The now poor vasculature results in 
hypoxia, which will induce the release of pro-angiogenetic factors, including VEGF and 
PDGF.  These signals promote the pathologic vessel growth at the interface between retina 
and vitreous until P22. Vascular formation at different stages (P14, P17, and P20) will be 
documented by whole-mount isolectin stain.  Expression levels of genes related to 
angiogenesis and the BMP pathway will also be determined by real-time PCR.  These data 
will provide direct evidence to identify the role of Bmper in angiogenesis. 
In conclusion, we have identified Cox2 as one of the essential downstream targets in 
BMP-induced angiogenesis by in vitro reporter assays and EC functional assays.  Cox2 may 
also serve as an important mediator in connecting the BMP pathway with other pro-
angiogenetic growth factor signals such as VEGF.  Similar approaches can be applied to 
characterize potential downstream targets in BMP-mediated vascular remodeling events.  
Second, we examined the role of a BMP extracellular regulator, Bmper, in heart and lung 
formation during early development using an in vivo targeted deletion study.  Bmper 
deficiency caused not only abnormalities in lung morphogenesis with the overgrowth of 
distal lung epithelium and mesenchyme, but also hypertrophy in cultured cardiomyocytes.  
An elevated BMP signaling activity was observed in Bmper null cardiomyocytes by real-time 
PCR, strongly suggesting an anti-BMP effect of Bmper in cardiomyocytes.  Further 
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 characterization of Bmper deficient mice will reveal more helpful information in elucidating 
the tissue specific opposing activities of Bmper on the BMP pathway.  As Cox2 mediates 
BMP downstream effects and Bmper serves as a regulator for proper BMP activity, they both 
can serve as therapeutic targets in heart disease and in tumorigenesis resulting from abnormal 
BMP activities. 
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